Among the medicines on A.K. Pharma’s product range that generate significant Google search traffic but relatively few clicks, Sybrava stands out. Over 2,000 impressions per month at position 5 — meaning it appears on the first page of Google for thousands of searches — but a click-through rate of under 1%. That gap between visibility and engagement is almost always a content problem, not a ranking problem. People are finding the page but not finding enough information to click through. This article is the information. Whether you are an oncologist looking for sourcing context, a hospital pharmacist managing HER2-positive breast cancer procurement, or a patient or family member trying to understand what Sybrava is and why it has been prescribed, here is what you need to know.